Status:
RECRUITING
Genomics and COVID-19 Vaccine Adverse Events
Lead Sponsor:
University of British Columbia
Collaborating Sponsors:
Centers for Disease Control and Prevention
Conditions:
Vaccine Adverse Reaction
Eligibility:
All Genders
5-99 years
Brief Summary
Vaccines routinely used are extremely safe; however, severe adverse events to vaccines do occur. As vaccination against COVID-19 has begun, adverse events to the vaccine, particularly Guillain-Barré s...
Detailed Description
Purpose: Reduce the risk of COVID-19 vaccine-induced adverse events (i.e., GBS, VITT/TTS, and myocarditis/pericarditis) through improved understanding of the biology underlying these severe adverse e...
Eligibility Criteria
Inclusion
- Case: Any patient who received COVID-19 vaccines and developed GBS, VITT/TTS, or myocarditis/pericarditis after vaccination
- Control: Any participant who received COVID-19 vaccines and does not experience GBS, VITT/TTS, or myocarditis/pericarditis.
Exclusion
- Individuals who have not received a COVID-19 vaccine
- Individuals who are unable to provide informed consent
Key Trial Info
Start Date :
June 24 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
6325 Patients enrolled
Trial Details
Trial ID
NCT05212792
Start Date
June 24 2022
End Date
December 1 2025
Last Update
December 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
British Columbia Children's Hospital Research Institute
Vancouver, British Columbia, Canada, V5Z 4H4